Bristol-Myers Squibb Co.'s cholesterol-lowering drug Pravachol reduced the risk of heart attack or death from heart disease for at least 10 years after male patients stopped taking the statin, researchers report. The study further supports previous data that confirms the long-term cardiac benefits of statins, which are commonly prescribed indefinitely, especially for people with heart disease.

Related Summaries